Valneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy

Valneva and partner Pfizer reported their Lyme disease vaccine candidate achieved greater than 70% efficacy in a large Phase 3 study. Despite the strong clinical readout, Valneva's stock dropped sharply, indicating market skepticism or concerns about commercialization, regulatory pathway, or deal economics.

Analysis

Valneva and partner Pfizer reported their Lyme disease vaccine candidate achieved greater than 70% efficacy in a large Phase 3 study. Despite the strong clinical readout, Valneva's stock dropped sharply, indicating market skepticism or concerns about commercialization, regulatory pathway, or deal economics.